Telemedicine Based Remote Home Monitoring After Liver Transplantation (TelehealthOLT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03878329 |
|
Recruitment Status :
Completed
First Posted : March 18, 2019
Last Update Posted : July 1, 2021
|
Sponsor:
University of Cincinnati
Information provided by (Responsible Party):
Shimul Shah, University of Cincinnati
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A significant opportunity exists to involve patients and their caregivers in more effective perioperative care and transition to home for transplant patients. Stakeholders were engaged through the University of Cincinnati Liver Transplant Program to prioritize changes in improving post transplant care. The initial findings indicated that increasing "care between visits" is the top priority for patients for improving function, quality of life and independence. Building on existing telehealth research, an enhanced home management program (HMP) to leverage and improve patient self-care following liver transplantation was developed, specifically by improving adherence, reducing readmissions and improving the transition from hospital to home. The improvement of care may have profound effect in the first 90 days after transplant on important long-term health parameters that affect clinical outcomes such as depression, weight gain, blood pressure control and diabetes management. With patient engagement, a randomized controlled trial is proposed comparing traditional provider-based care vs. traditional care with HMP. These two arms will need 50 patients in each arm with a 0.5 year follow up. Patients have said that the primary outcomes are quality of life, function and independence. To that end, the primary study outcomes are assessment of adherence, readmissions (90-day), patient satisfaction. The HMP model will advise providers, health care systems, and transplant centers how to improve patient care, especially among those at greatest risk of poor outcomes specifically minorities and those of low socioeconomic status.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Liver Failure Liver Transplant; Complications | Behavioral: remote home monitoring | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized Controlled Trial |
| Masking: | None (Open Label) |
| Masking Description: | Non-blinded. |
| Primary Purpose: | Prevention |
| Official Title: | Randomized Prospective Trial of Telemedicine Based Remote Home Monitoring After Liver Transplantation |
| Actual Study Start Date : | January 1, 2017 |
| Actual Primary Completion Date : | January 1, 2019 |
| Actual Study Completion Date : | December 1, 2020 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
No Intervention: standard of care
standard of care treatment
|
|
|
Experimental: remote home monitoring
use of telemedicine based remote home monitoring
|
Behavioral: remote home monitoring
Will use telemedicine to guide behavior changes in outcomes |
Primary Outcome Measures :
- 90- day readmission [ Time Frame: 90 days ]Assess readmission
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female subjects (≥ 18 years old) who are liver transplant recipients.
- Discharged home within 45 days of liver transplant.
- Able and willing to provide informed consent.
Exclusion Criteria:
- Post-transplant admission and care provided by University of Cincinnati Medical Center or rehab facility > 45 days after liver transplant.
- Unable to have 4G wireless connectivity or wifi in their home.
- Patient has any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the investigator.
- Inability to cooperate or communicate with the investigator.
No Contacts or Locations Provided
Publications of Results:
| Responsible Party: | Shimul Shah, Professor of Surgery, Chief, Solid Organ Transplantation, Department of Surgery, University of Cincinnati |
| ClinicalTrials.gov Identifier: | NCT03878329 |
| Other Study ID Numbers: |
TelehealthOLT |
| First Posted: | March 18, 2019 Key Record Dates |
| Last Update Posted: | July 1, 2021 |
| Last Verified: | June 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Protocol will be share |
| Supporting Materials: |
Study Protocol |
| Time Frame: | 1 year after study completed. |
| Access Criteria: | investigator with HIPAA compliance |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Liver Failure Hepatic Insufficiency Liver Diseases Digestive System Diseases |

